All content on this site is intended for healthcare professionals only. By acknowledging this message and accessing the information on this website you are confirming that you are a Healthcare Professional. If you are a patient or carer, please visit the MPN Advocates Network.

  TRANSLATE

The mpn Hub website uses a third-party service provided by Google that dynamically translates web content. Translations are machine generated, so may not be an exact or complete translation, and the mpn Hub cannot guarantee the accuracy of translated content. The mpn and its employees will not be liable for any direct, indirect, or consequential damages (even if foreseeable) resulting from use of the Google Translate feature. For further support with Google Translate, visit Google Translate Help.

The MPN Hub is an independent medical education platform, sponsored by AOP Health and GSK, and supported through an educational grant from Bristol Myers Squibb and Incyte. The funders are allowed no direct influence on our content. The levels of sponsorship listed are reflective of the amount of funding given. View funders.

Now you can support HCPs in making informed decisions for their patients

Your contribution helps us continuously deliver expertly curated content to HCPs worldwide. You will also have the opportunity to make a content suggestion for consideration and receive updates on the impact contributions are making to our content.

Find out more

Blinatumomab + TKI for de novo or relapsed Ph+ B-ALL

Oct 15, 2025

Learning objective: After reading this article, learners will be able to cite a new clinical development in acute lymphoblastic leukemia.


Results from a single-center, retrospective analysis comparing blinatumomab + tyrosine kinase inhibitors (TKIs) vs pediatric-inspired chemotherapy + TKI protocols in 47 patients with Philadelphia-positive B-cell acute lymphoblastic leukemia (Ph+ B-ALL) were recently published in the International Journal of Cancer by Stolz et al.

Key data: Despite patients in the blinatumomab cohort being significantly older (p < 0.05) and having higher rates of active central nervous system (CNS) disease, overall survival (OS), progression-free survival (PFS), and non-relapse mortality (NRM) were comparable between patients treated with blinatumomab + TKI vs conventional chemotherapy + TKI regimens (2 year-OS, 87% vs 78%; PFS, 81% vs 54%; NRM, 6.3% vs 14%, respectively). Severe treatment-related adverse events (TRAEs) were significantly more common in the chemotherapy group than the blinatumomab cohort. 

Key learning: Blinatumomab + TKI represents a safe and effective chemotherapy-free approach for patients with de novo or relapsed Ph+ B-ALL, offering comparable survival outcomes with significantly reduced treatment-related toxicity compared with standard chemotherapy-based regimens.

References

Please indicate your level of agreement with the following statements:

The content was clear and easy to understand

The content addressed the learning objectives

The content was relevant to my practice

I will change my clinical practice as a result of this content